通化金马药业集团股份有限公司监事会对公司 2024 年度内部控制自我评价报告的审核意见 根据深圳证券交易所《上市公司内部控制指引》等有关规定，监 事会对公司 2024 年度内部控制自我评价报告发表意见如下： 公司监事会认真审阅了公司 2024 年度内部控制自我评价报告， 认为公司根据实际情况和管理需要，建立健全了完整、合理的内部控 制制度，保证了公司经营活动的有序开展，切实保护了公司全体股东 的根本利益；公司 2024 年度内部控制自我评价报告全面、客观、真 实地反映了公司目前的内部控制体系建设、运作、制度执行和监督的 实际情况，不存在重大缺陷。监事会同意公司 2024 年度内部控制自 我评价报告事项。 通化金马药业集团股份有限公司监事会 2025 年 4 月 17 日 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-16 通化金马药业集团股份有限公司 第十一届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会第八次会议通知于 2025 年 4 月 8 日以微信、电子邮件形式送达全体董事。 2. 2025 年 4 月 17 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事 9 人，实到董事 9 人。 4.会议由董事长张玉富先生主持。监事会成员及部分高管人员列席了本次会 议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、董事会会议审议情况 1、审议并通过公司 2024 年度董事会工作报告 《2024 年度董事会工作报告》具体内容详见同日公司在巨潮资讯网披露的 公司《2024 年年度报告》第三节"管理层讨论与分析"、第四节"公司治理" 及 第六节" 重要事项"等章节。 本议案需提交公司 2024 年年度股东大会审议。 公司独立董事向董事会提交了《2024 年 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-19 通化金马药业集团股份有限公司 2024年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 2025 年 4 月 17 日，通化金马药业集团股份有限公司（以下简称"公司"） 召开第十一届董事会第八次会议、第十一届监事会第八次会议，审议通过了《公 司 2024 年度利润分配方案》。公司董事会和监事会均认为本次利润分配方案符合 《公司法》《关于进一步落实上市公司现金分红有关事项的通知》《上市公司监管 指引第 3 号——上市公司现金分红》和《公司章程》关于利润分配的相关规定， 综合考虑了公司实际经营情况和可持续性发展，不存在损害公司和全体股东特别 是中小股东利益的情形。 根据《公司法》《公司章程》相关规定，本次利润分配方案尚需提交公司 2024 年年度股东大会审议。 二、2024 年度利润分配方案的基本情况 经北京德皓国际会计师事务所（特殊普通合伙）审计并出具（德皓审字 [2025]00000924 号）的审计报告确认公司 2024 年度归属于上市公司股东的净利 润 ...

Financial Performance - The company reported significant financial metrics in the annual report, including total revenue and net profit figures[14]. - The company's operating revenue for the reporting period was ¥1,322,557,724.02, a decrease of 10.23% compared to ¥1,473,345,301.05 in the previous period[21]. - Net profit attributable to shareholders was ¥56,437,325.61, representing an increase of 28.46% from ¥43,933,703.90 in the previous period[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥47,974,388.91, up 63.04% from ¥29,424,093.57 in the previous period[21]. - The net cash flow from operating activities was ¥162,746,489.78, an increase of 44.31% compared to ¥112,779,071.13 in the previous period[21]. - Basic and diluted earnings per share were both ¥0.06, reflecting a 20.00% increase from ¥0.05 in the previous period[21]. - Total assets at the end of the reporting period were ¥4,483,618,602.64, a decrease of 0.79% from ¥4,519,244,365.23 at the end of the previous year[21]. - Net assets attributable to shareholders were ¥2,255,397,745.17, down 2.69% from ¥2,317,662,919.56 at the end of the previous year[21]. Shareholder Information - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[6]. - The company has undergone changes in its major shareholders, with a shift in control to Yu Lanjun[19]. - The largest shareholder, Yu Lanjun, holds 19.66% of the shares, totaling 190,000,000 shares, with no changes during the reporting period[189]. - The second-largest shareholder, Li Jia, holds 4.24% of the shares, totaling 40,999,900 shares, with no changes during the reporting period[189]. - The company reported a total of 46,481 shareholders at the end of the reporting period[189]. - The total number of shares held by the top 10 shareholders includes significant pledges, with Yu Lanjun pledging 150,000,000 shares[189]. - The company has a total of 966,494,707 shares outstanding, with no new shares issued during the reporting period[185]. - The restricted shares held by executives are subject to a 25% transfer limit per year[187]. Corporate Governance - The company has maintained strict compliance with corporate governance regulations, ensuring that all shareholders, especially minority shareholders, are treated equally[90]. - The board of directors consists of 9 members, including 3 independent directors, and operates through four specialized committees[91]. - The company has established independent operations in terms of assets, personnel, finance, and business, ensuring no interference from the controlling shareholder[93]. - The company has a strong commitment to social responsibility, actively engaging in public welfare and environmental protection initiatives[93]. - The company has maintained a stable management team with no significant changes in senior management roles[101]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 8.6786 million[111]. - The company held multiple board meetings throughout the reporting period, with significant decisions documented in announcements[112][113]. Risk Management - The management discussion section outlines potential risks in the company's future operations[5]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in its reports[5]. - The company acknowledges risks related to policy changes, product quality control, R&D challenges, and environmental compliance, and is taking proactive measures to mitigate these risks[83][84]. - The company is enhancing its R&D team and processes to ensure effective risk analysis and management throughout the new drug development cycle[84]. Research and Development - The company is actively involved in the development of new products and technologies, as indicated by recent government initiatives to enhance the standards and quality of traditional Chinese medicine[31]. - The company maintains a comprehensive product portfolio covering multiple therapeutic areas, including oncology and cardiovascular diseases[41]. - The company holds a total of 44 invention patents and 76 utility model patents, with 10 invention patents currently under review[42]. - The company is advancing the development of a new drug, Amber Tetrahydroaminoacridine Tablets, which has received a notice of acceptance for market application from the National Medical Products Administration[44]. - R&D investment increased by 16.69% to ¥67,545,426.74 in 2024, compared to ¥57,885,662.87 in 2023, with R&D expenditure as a percentage of revenue rising from 3.93% to 5.11%[58]. Environmental Compliance - The company strictly adheres to national environmental protection laws and industry standards, ensuring compliance in its production processes[136]. - The company reported a total COD discharge of 2.89 tons, with an average concentration of 14.69 mg/L, adhering to the GB21906-2008 standard[137]. - The company achieved a total nitrogen discharge of 51 tons per year, with ammonia nitrogen discharge at 4.73 tons per year, complying with the relevant pollution discharge standards[137]. - The company’s atmospheric emissions included a sulfur discharge of 25 tons per year, with a nitrogen oxide concentration of 22.43 mg/m³, meeting the GB13271-2014 standard[138]. - The company maintained a nitrogen oxide discharge of 0.107 tons, complying with national emission standards[138]. - The company has invested over 19 million yuan in VOCs emission control, which has been operational since 2021, ensuring compliance with air pollution standards[139]. Financial Independence - The company maintains financial independence by establishing a complete and standardized financial accounting system and internal control mechanisms, ensuring no shared bank accounts with controlling shareholders[94]. - The internal control evaluation report indicates that 100% of the company's total assets and operating income were included in the evaluation scope, reflecting a complete assessment[132]. - The internal control audit report issued by Beijing Dehao International Accounting Firm confirmed that the company maintained effective internal controls over financial reporting as of December 31, 2024[134]. Market Position - The company is positioned in the pharmaceutical industry, which is supported by national policies aimed at promoting the development of traditional Chinese medicine[30]. - The pharmaceutical industry is experiencing rapid growth due to increasing healthcare demands driven by rising living standards and an aging population, despite facing challenges such as rising costs and intense competition[80]. - The company is focused on expanding its market presence and enhancing product development capabilities[108]. Employee Management - The total number of employees at the end of the reporting period is 1,532, with 668 in the parent company and 864 in major subsidiaries[121]. - The professional composition includes 834 production personnel, 218 sales personnel, 218 technical personnel, 53 financial personnel, and 209 administrative personnel[121]. - The company has implemented a training program focused on enhancing employees' comprehensive qualities and professional skills to strengthen core competitiveness[123]. Audit and Compliance - The audit opinion for the financial statements was a standard unqualified opinion, confirming the fair presentation of the company's financial position as of December 31, 2024[200]. - The company has appointed Beijing Dehao International Accounting Firm for the 2024 annual audit, with an audit fee of 1.05 million RMB[159]. - There were no major lawsuits or arbitration matters during the reporting period[162].

通化金马（000766）公告，2024年营业收入13.23亿元，同比下降10.23%。归属于上市公司股东的净利 润5643.73万元，同比增长28.46%。基本每股收益0.06元/股，同比增长20.00%。公司计划不派发现金红 利，不送红股，不以公积金转增股本。 ...

通化金马药业集团股份有限公司 Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 通化金马药业集团股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 内部控制审计报告 德皓内字[2025]00000054 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) 目 录 页 次 一、 内部控制审计报告 1-2 内 部 控 制 审 计 报 告 德皓内字[2025]00000054 号 通化金马药业集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了通化金马药业集团股份有限公司（以下简称金马 药业公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对 ...

通化金马药业集团股份有限公司 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 通化金马药业集团股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 通化金马药业集团股份有限公司 2024 年度非 经营性资金占用及其他关联资金往来情况汇 总表 1 控股股东及其他关联方资金占用情况的 专项说明 德皓核字[2025]00000723 号 德皓核字[2025]00000723 号关联方资金占用情况的专项说明 务报表的相关内容进行了核对，在所有重大方面未发现不一致。除了 对金马药业公司实施 2024 年度财务报表审计中所执行的对关联方交 易有关的审计程序外，我们未对汇总表所载资料执行额外的审计程序。 为了更好地理解金马药业公司 2024 年度控股股东及其他关联方资金 占用的情况，后附的汇总表应当与 ...

通化金马药业集团股份有限公司 通化金马药业集团股份有限公司 董事会 2025 年 4 月 17 日 董事会关于独立董事 2024 年度独立性自查情况的专项意见 根据《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号--主板上市公司规范运作》等的规 定，通化金马药业集团股份有限公司（以下简称"公司"）董事会就公司独立董 事 2024 年度的独立性情况进行评估并出具如下专项意见： 经核查 2024 年度公司在任独立董事吕桂霞女士、张玲女士的任职经历以及 其签署的相关自查文件，上述人员不存在妨碍其进行独立客观判断的关系，不存 在影响独立性的情况，符合《上市公司独立董事管理办法》、《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等监管规则中关于独 立董事独立性的相关要求。 ...